Clinical Trials Browser

INDUSTRY × Breast Neoplasms × Dasatinib × Clear all

NCT00696072 2016-06-13

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Phase 2 Completed

120 enrolled 13 charts

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Phase 2 Completed

155 enrolled 19 charts

Breast Neoplasms

NCT00371345 2011-04-26

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase 2 Completed

92 enrolled 27 charts

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT00371254 2011-03-15

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Phase 2 Completed

55 enrolled 28 charts

Breast Neoplasms, Neoplasm Metastasis, Recurrence